Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836734 | 1.00 | RIPK1 (0.51) | RIPK1LMNAKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL15983796 | 0.86 | LMNA (0.49) | RIPK1LMNAKDM4EL3MBTL1SLC22A12 | |
| SCHEMBL16393647 | 0.85 | RIPK1 (0.47) | RIPK1LMNAKDM4EALDH1A1CTSS | |
| SCHEMBL19182690 | 0.83 | GABRA1 (0.48) | RIPK1LMNAKDM4EL3MBTL1SLC22A12 | |
| SCHEMBL24140655 | 0.80 | RIPK1 (0.47) | RIPK1ALDH1A1CTSSCTSKPOLB | |
| SCHEMBL1114878 | 0.79 | AKR1B1 (0.53) | LMNAKDM4EL3MBTL1POLBTAAR1 | |
| SCHEMBL4458475 | 0.79 | KDM4E (0.51) | LMNAKDM4EL3MBTL1ALDH1A1POLB | |
| SCHEMBL3093272 | 0.79 | RIPK1 (0.49) | RIPK1LMNAKDM4EALDH1A1CTSS | |
| SCHEMBL12802659 | 0.78 | RIPK1 (0.49) | RIPK1ALDH1A1POLBHPGDKMT2A | |
| SCHEMBL22175384 | 0.78 | RIPK1 (0.43) | RIPK1LMNAKDM4EALDH1A1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA, INC. | 2022-10-13 | — | — | US | disclosed |
| CN-114891034-A | TML type trigger molecule and preparation method and application thereof | 闽都创新实验室 | 2022-08-12 | — | — | CN | disclosed |
| US-11400097-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| CN-107501241-B | Compounds, pharmaceutical compositions containing them and their use in the treatment of proliferative diseases | 梅制药公司 | 2020-10-13 | — | — | CN | disclosed |
| US-20200316080-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10603324-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10335415-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190083506-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS, INC. | 2019-03-21 | — | — | US | disclosed |
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| WO-2014059202-A1 | GUANIDINE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014059214-A1 | GUANIDINE AND AMINE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014059214-A1 | GUANIDINE AND AMINE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-17 | — | — | WO | disclosed |
| EP-2691384-A1 | (ALPHA- SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5 -TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THESE COMPOUNDS FOR USE IN TREATING PROLIFERATIVE DISEASES | MEI Pharma, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| WO-2013056060-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013056034-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2013056034-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| WO-2012135160-A1 | (ALPHA- SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5 -TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THESE COMPOUNDS FOR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120252802-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | PATHWAY THERAPEUTICS INC. (US) | 2012-10-04 | — | — | US | disclosed |
| EP-0544287-A1 | Gem-dialkyl-7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E.R. SQUIBB & SONS, INC. (US) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316080-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | RIPK1 4411/4885LMNA 414/4885KDM4E 3448/4885 |
| US-12059422-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | RIPK1 4411/4885LMNA 414/4885KDM4E 3448/4885 |
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | RIPK1 4411/4885LMNA 414/4885KDM4E 3448/4885 |
| US-20120252802-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | RIPK1 4411/4885LMNA 414/4885KDM4E 3448/4885 |
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | TFPI, TFPI2, KLKB1 | RIPK1 1883/4885LMNA 1643/4885KDM4E 492/4885 |
| US-10335415-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | RIPK1 4411/4885LMNA 414/4885KDM4E 3448/4885 |
| US-10603324-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | RIPK1 4411/4885LMNA 414/4885KDM4E 3448/4885 |
| US-20190083506-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | RIPK1 4411/4885LMNA 414/4885KDM4E 3448/4885 |
| US-11400097-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | RIPK1 4411/4885LMNA 414/4885KDM4E 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.